KEGG   NETWORK: N00001
Entry
N00001                      Network                                
Name
EGF-EGFR-RAS-ERK signaling pathway
Definition
EGF -> EGFR -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1
  Expanded
1950 -> 1956 -> 2885 -> (6654,6655) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 595
Class
nt06260 Colorectal cancer
nt06263 Hepatocellular carcinoma
nt06265 Bladder cancer
nt06266 Non-small cell lung cancer
nt06268 Melanoma
nt06270 Breast cancer
nt06271 Endometrial cancer
nt06273 Glioma
nt06274 Thyroid cancer
nt06276 Chronic myeloid leukemia
nt06210 ERK signaling (cancer)
nt06162 Hepatitis B virus (HBV)
nt06163 Hepatitis C virus (HCV)
nt06170 Influenza A virus (IAV)
nt06167 Human cytomegalovirus (HCMV)
nt06166 Human papillomavirus (HPV)
Type
Reference
Pathway
hsa04010  MAPK signaling pathway
Gene
1950  EGF; epidermal growth factor
1956  EGFR; epidermal growth factor receptor
2885  GRB2; growth factor receptor bound protein 2
6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1
6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2
3265  HRAS; HRas proto-oncogene, GTPase
3845  KRAS; KRAS proto-oncogene, GTPase
4893  NRAS; NRAS proto-oncogene, GTPase
369  ARAF; A-Raf proto-oncogene, serine/threonine kinase
673  BRAF; B-Raf proto-oncogene, serine/threonine kinase
5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase
5604  MAP2K1; mitogen-activated protein kinase kinase 1
5605  MAP2K2; mitogen-activated protein kinase kinase 2
5594  MAPK1; mitogen-activated protein kinase 1
5595  MAPK3; mitogen-activated protein kinase 3
595  CCND1; cyclin D1
Reference
PMID:17409820
  Authors
Molina JR, Adjei AA
  Title
The Ras/Raf/MAPK pathway.
  Journal
J Thorac Oncol 1:7-9 (2006)
DOI:10.1016/S1556-0864(15)31506-9
Reference
PMID:24840079
  Authors
Zhao Y, Adjei AA
  Title
The clinical development of MEK inhibitors.
  Journal
Nat Rev Clin Oncol 11:385-400 (2014)
DOI:10.1038/nrclinonc.2014.83
Reference
PMID:20149254
  Authors
Fremin C, Meloche S
  Title
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.
  Journal
J Hematol Oncol 3:8 (2010)
DOI:10.1186/1756-8722-3-8
LinkDB

DBGET integrated database retrieval system